<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2318">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542876</url>
  </required_header>
  <id_info>
    <org_study_id>AYU/DSSR/03</org_study_id>
    <nct_id>NCT04542876</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection</brief_title>
  <official_title>Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarogyam UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarogyam UK</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence of asymptomatic patients poses a significant challenge to the prevention and&#xD;
      treatment of the epidemic.There have not been any treatment options that reduce the viral&#xD;
      load or preventive options that reduce the risk of developing severe conditions.Therefore,&#xD;
      present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in&#xD;
      asymptomatic patients with COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">August 18, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic clearance</measure>
    <time_frame>14 days</time_frame>
    <description>Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Stay</measure>
    <time_frame>14 days</time_frame>
    <description>Total duration of stay in hospital for complete recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant adverse effects</measure>
    <time_frame>14 days</time_frame>
    <description>Clinically relevant adverse effects of Guduchi Ghan Vati were reported using Adverse Drug Reaction reporting form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>change from baseline to 14 days</time_frame>
    <description>Routine blood tests were performed to assess complete blood counts, blood biochemistry parameters {Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin} and immunoglobulines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ayurveda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guduchi Ghan Vati</intervention_name>
    <description>Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.</description>
    <arm_group_label>Ayurveda</arm_group_label>
    <other_name>Giloya</other_name>
    <other_name>Amrita</other_name>
    <other_name>Tinosporia Cordifolus</other_name>
    <other_name>Guduchi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All hospitalised cases above 18 years of age,&#xD;
&#xD;
          -  Diagnosed with Covid-19&#xD;
&#xD;
          -  Asymptomatic at the time of admission&#xD;
&#xD;
          -  Agree to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms relating to Covid-19&#xD;
&#xD;
          -  Severe vomiting&#xD;
&#xD;
          -  Respiratory failure or requiring mechanical ventilation&#xD;
&#xD;
          -  Patients having alanine transaminase (ALT) or aspartate transaminase (AST) &gt; 5 times&#xD;
             the upper range of normal limits&#xD;
&#xD;
          -  Patients with Covid-19 in critical condition or ARDS or NIAD 8 -point ordinal score-2&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Malignant,&#xD;
&#xD;
          -  Chronic renal failure or&#xD;
&#xD;
          -  On immunosuppressive medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Kumar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neha Sharma</last_name>
    <role>Study Director</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</name>
      <address>
        <city>Jodhpur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

